Skip to main content

Drug Interactions between bictegravir / emtricitabine / tenofovir alafenamide and Mi-Acid II

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

aluminum hydroxide bictegravir

Applies to: Mi-Acid II (aluminum hydroxide / magnesium hydroxide / simethicone) and bictegravir / emtricitabine / tenofovir alafenamide

Products that contain aluminum, calcium, iron, magnesium or other minerals such as antacids and supplements may interfere with the absorption of bictegravir and reduce its effectiveness in treating HIV infection. Additionally, it may lead to development of viral resistance to this and various other HIV medications that are currently used for treatment. When used with antacids, you should generally take bictegravir on an empty stomach at least two hours before the antacid. Avoid taking bictegravir simultaneously with, or 2 hours after, antacid dosing whenever possible. When used with multivitamin or mineral supplements, you may take bictegravir and supplements together at the same time, but with food. Avoid taking bictegravir on an empty stomach simultaneously with, or 2 hours after, dosing of supplements. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed, or if you have trouble separating the dosing times. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Major

magnesium hydroxide bictegravir

Applies to: Mi-Acid II (aluminum hydroxide / magnesium hydroxide / simethicone) and bictegravir / emtricitabine / tenofovir alafenamide

Products that contain aluminum, calcium, iron, magnesium or other minerals such as antacids and supplements may interfere with the absorption of bictegravir and reduce its effectiveness in treating HIV infection. Additionally, it may lead to development of viral resistance to this and various other HIV medications that are currently used for treatment. When used with antacids, you should generally take bictegravir on an empty stomach at least two hours before the antacid. Avoid taking bictegravir simultaneously with, or 2 hours after, antacid dosing whenever possible. When used with multivitamin or mineral supplements, you may take bictegravir and supplements together at the same time, but with food. Avoid taking bictegravir on an empty stomach simultaneously with, or 2 hours after, dosing of supplements. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed, or if you have trouble separating the dosing times. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

Major

aluminum hydroxide food

Applies to: Mi-Acid II (aluminum hydroxide / magnesium hydroxide / simethicone)

Citrate, or citric acid, can increase the absorption of aluminum hydroxide. This may lead to elevated blood levels of aluminum, particularly in individuals with reduced kidney function, since aluminum is primarily eliminated by the kidneys. Excess aluminum may deposit and cause problems in various tissues including bone, brain, heart, liver, muscles, and spleen. Over time, weak bones, bone pain, fractures, skeletal deformity, brain disorders, and anemia may develop. Talk to your doctor before using aluminum hydroxide if you have kidney impairment or are on hemodialysis. You should avoid or limit the consumption of citrate-containing foods and beverages (e.G., soft drinks, citrus fruits, fruit juices) during treatment with aluminum hydroxide. Be aware that some effervescent and dispersible drug formulations may also contain citrate and should be restricted as well. Even if you do not have kidney problems, it may be best to separate the dosing of aluminum hydroxide and citrate-containing products by 2 to 3 hours. Talk to a healthcare professional if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

When aluminum hydroxide is taken during enteral nutrition therapy (tube feeding), the tube may get clogged. Therefore, aluminum hydroxide should not be mixed with or given after high-protein tube feedings. The dose should be separated from the feeding by as much as possible, and the tube should be thoroughly flushed before administration of the dose.

Switch to professional interaction data

Minor

tenofovir food

Applies to: bictegravir / emtricitabine / tenofovir alafenamide

Information for this minor interaction is available on the professional version.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.